CD274 and nasopharyngeal carcinoma: Respective of PD-L1 expression status, camrelizumab in combination with apatinib exhibited encouraging antitumor activity in platinum-resistant (cohort 1) and in PD-1 inhibitor-resistant (cohort 2) RM-NPC patients.